Get in touch with G&L Scientific today!

London   |   Belfast   |   Marlow
E: hello@gandlscientific.com
Warren, NJ   |   Boston, MA   |   San Diego, CA   |   Los Angeles, CA  |  Boca Raton, FL
E: hello@gandlscientific.com

EMA approvals rise by almost 50 per cent in 2020

January 28, 2021

While COVID-19 and its associated vaccines dominated news headlines in 2020, the last twelve months have been notable for significant progress in the world of healthcare.

Figures published recently by the European Medicines Agency (EMA) show an almost 50 per cent increase during 2020 for marketing authorisation recommendations for new medicines compared to the same period in 2019 (97 new medicines compared to 66 the previous year).

Of these 97 medicines, 39 contained new, active substances which had never been authorised in the European Union before.

As well as the high-profile recommendation for the approval of the Pfizer/BioNTech COVID-19 vaccine, the EMA gave the green light to a range of medicines that represented significant progress in their respective therapeutic areas designed to treat cancers, HIV, and rare metabolic disorders like metachromatic leukodystrophy and MCL.

Meanwhile, in the United States, the Food and Drug Administration (FDA) recorded a 10 per cent increase in approvals for new medicines during 2020 (53 compared to 48 in 2019).

The full EMA report can be read here

For further information contact:

Jonathan Walmsley
E: jwalmsley@gandlscientific.com
T: 0203 143 2195

Back to news

G&L Scientific Holdings

Keep up to date with the latest industry news and trends
Newsletter Signup
Validation

Worldwide Locations

|
G&L Scientific G&L Scientific G&L Scientific G&L Scientific G&L Scientific